Hamburg, Germany

Mark Joseph Tebbe

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 7.3

ph-index = 5

Forward Citations = 131(Granted Patents)


Location History:

  • Indianapolis, IN (US) (1996 - 2008)
  • Durham, NC (US) (2009)
  • Zionsville, IN (US) (2010)
  • Hamburg, DE (2008 - 2013)

Company Filing History:


Years Active: 1996-2013

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Unveiling the Legacy of Inventor Mark Joseph Tebbe

Introduction:

Mark Joseph Tebbe, a prolific inventor hailing from Hamburg, Germany, has left an indelible mark in the field of pharmaceutical innovation. With a impressive portfolio of 11 patents to his name, Tebbe is renowned for his groundbreaking work in peptidomimetic protease inhibitors.

Latest Patents:

Tebbe's latest patents revolve around peptidomimetic compounds designed as protease inhibitors, particularly focusing on serine protease inhibitors and specifically on hepatitis C NS3 protease inhibitors. His inventions not only encompass the compounds themselves but also their preparation methods, pharmaceutical compositions, and treatment applications aimed at inhibiting HCV protease or addressing related physiological conditions.

Career Highlights:

Having worked at esteemed companies such as Eli Lilly and Company and Vertex Pharmaceuticals, Inc., Tebbe has honed his expertise in pharmaceutical research and development. His journey is defined by a relentless pursuit of innovative solutions in the realm of protease inhibition, especially in the context of combatting HCV infections.

Collaborations:

Throughout his career, Tebbe has collaborated with notable professionals in the field, including Frantz Victor and Shawn Christopher Miller. Together, they have synergized their skills and knowledge to advance the boundaries of pharmaceutical science and pave the way for novel treatment modalities.

Conclusion:

In conclusion, Mark Joseph Tebbe stands as a luminary in the world of pharmaceutical innovation, with his patents serving as testaments to his ingenuity and dedication to advancing healthcare solutions. His contributions to the development of peptidomimetic protease inhibitors have not only reshaped therapeutic approaches for HCV infections but have also inspired a new wave of research in the field. Mark Joseph Tebbe's legacy continues to inspire aspiring inventors and researchers worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…